Press Releases

Press Releases

  1. BTG Launches βETA™ Radiation Safety Programme, to Reduce the Risk of Radiation Exposure for Healthcare Professionals and Patients

  2. BTG receives Health Canada approval for DC Bead LUMI™

  3. CMS Grants Vistogard® New Technology Add-on Payment Status Effective 1 October 2016

  4. BTG plc: Appointment of Non-executive Director

  5. BTG plc: Annual General Meeting

  6. Varithena® Earns FDA Approval for 30 Day Post-Activation Shelf Life

  7. BTG completes the acquisition of Galil Medical

  8. BTG Joins Global Liver Institute Partnership Network to Transform Care for Liver Cancer Patients

  9. New study highlights potential cost savings when using yttrium-90 glass microspheres for treatment of hepatocellular carcinoma

  10. BTG plc: Final Results 2016

  11. BTG plc acquires Galil Medical, a leader in cryoablation

  12. BTG plc: Close Period Update

  13. BTG to Initiate Multi-Centre TARGET Study Evaluating Dosimetry for 90Y Radioembolisation Therapy in Patients With Hepatocellular Carcinoma

  14. BTG announces US launch of LC Bead LUMI™, ground-breaking radiopaque embolic bead

  15. BTG International Canada Expands Operations To Directly Sell Interventional Oncology Products

  16. New Data from Largest Prospective Study on CroFab® for Treatment of Copperhead Snake Envenomation

  17. First Patient Treated With LC Bead LUMI™ Radiopaque Embolic Bead Supported by Philips Live Image Guidance

  18. First Patients in South Korea Receive TheraSphere® Radioembolisation Treatment

  19. BTG Announces Presentation of New Vistogard® (uridine triacetate) Data at American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO-GI)